This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: Americord Registry
Americord Registry Offers Exclusive Service Preserving Stem Cells From Cord Tissue and Placenta Tissue
New York, NY (PRWEB) November 26, 2012
This month, The Ontario Genomics Institute, a private not-for-profit life sciences company made an investment in Toronto-based Tissue Regenerative Therapeutics (TRT), a company that aims to use umbilical mesenchymal stem cells (MSCs) to treat a variety of serious medical conditions. This investment will be used by TRT to take the next steps toward initiating human clinical trials. This comes just months after California’s UC Davis Health System received $53 million in grants to conduct research studies designed to lead to U.S. Food and Drug Administration approval of human clinical trials using MSCs.
MSCs, which can easily be harvested from umbilical cord tissue and placenta tissue when a baby is born, are in fact currently the subject of over 200 clinical trials. While MSCs are not yet being used for medical therapies, research has indicated that they hold the promise of being able to someday treat debilitating conditions such as heart disease, type 1 diabetes, lung cancer, Parkinson’s Disease, and injuries to bones and cartilage.
Americord Registry offers the ability to preserve MSCs. “We are committed to helping parents-to-be expand their baby’s options for future medical treatment,” said Americord CEO Martin Smithmyer. “Offering the option to preserve MSCs from umbilical cord tissue and placenta tissue is just one of the ways that we are pioneering best-in-class services in the cord blood industry. We are also working closely with scientists to develop a proprietary product that will significant increase the volume of stem cells that can be preserved when a baby is born.”
Americord Registry also offers the ability to preserve stem cells from umbilical cord blood. Parents-to-be can preserve stem cells from just umbilical cord blood, from cord blood and cord tissue, or from cord blood, cord tissue and placenta tissue. For a comparison of Americord’s prices and services with other leading cord blood companies, visit Americord’s website.
About Americord Registry
Americord Registry is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord Registry's website at http://www.cordadvantage.com for more information. You may also find Americord Registry on Facebook and follow the company on Twitter.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/11/prweb10161689.htm